VivoSeq
Other

Luteal Phase Support

0

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Luteal Phase Support is an early-stage landscape with 0 programs across 1 company. The most active players are Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

28

clinical trials

Unknown status12 · 43%
Completed11 · 39%
Recruiting5 · 18%

Clinical Trials

Trial Activity

28 trials

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Recruiting·TThe University of Hong Kong·Phase 3·NCT04064840·784 enrolled
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06150703·652 enrolled
Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET
Recruiting·TThe University of Hong Kong·Phase 3·NCT03859921·716 enrolled
Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment
Recruiting·UUMC Utrecht·Phase 4·NCT05080569·1,008 enrolled
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
Recruiting·AART Fertility Clinics LLC·Phase 1·NCT05969795·342 enrolled
Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support
Completed·UUniversita di Verona·N/A·NCT03734770·149 enrolled
GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT
Completed·—·Phase 3·NCT02053779·328 enrolled
A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT01081652·238 enrolled
Luteal Phase Support in Insemination Cycles
Completed·TTampere University Hospital·Phase 4·NCT03115307·167 enrolled
Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)
Completed·IIBSA Institut Biochimique SA·Phase 3·NCT00827983·683 enrolled
Luteal Phase Support In IVF Women Using GnRH Agonist
Completed·NNational University of Malaysia·N/A·NCT04174378·222 enrolled
Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support
Completed·RRoberta Venturella·Phase 4·NCT02316626·246 enrolled
Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI
Completed·CCRG UZ Brussel·Phase 4·NCT03677336·30 enrolled
Comparison of the Effect of Subcutaneous Progesterone and Vaginal Progesterone for Luteal Phase Support
Completed·—·N/A·NCT05276531·146 enrolled
Dydrogesterone Versus Intravaginal Progesterone in the Luteal Phase Support
Completed·UUniversity of Zagreb·N/A·NCT01178931·853 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)